Truist Financial analyst Danielle Brill maintained a Buy rating on Maze Therapeutics, Inc. today and set a price target of $64.00.

Danielle Brill has given his Buy rating due to a combination of factors tied to the expanding APOL1 inhibitor opportunity in AMKD. Vertex’s positive Phase 2 data suggest APOL1 inhibition can benefit a much broader set of AMKD patients beyond FSGS, pointing to an addressable population exceeding 100,000 patients and supporting a multi‑billion‑dollar market in which MAZE can participate.

This enlarged market underpins the view that MAZE’s lead asset, MZE829, can achieve blockbuster‑level sales even if its efficacy and safety profile merely matches that of inaxaplin. Brill also highlights potential differentiation if MZE829 shows a cleaner hepatic safety profile amid transaminase elevation signals seen with Vertex’s drug, while noting that some uncertainty around diabetic AMKD remains but is directionally supportive. The price target is unchanged at $64, reflecting strengthened long‑term fundamentals without altering the valuation framework.

In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $110.00 price target.